Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension
ML Addison, P Ranasinghe… - Expert Review of Clinical …, 2023 - Taylor & Francis
Introduction Hypertension is the main global risk factor for cardiovascular disease. Despite
this, less than half of treated hypertensive patients are controlled. One reason for this is …
this, less than half of treated hypertensive patients are controlled. One reason for this is …
Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension
ML Addison, P Ranasinghe… - Expert Review of Clinical …, 2023 - research.ed.ac.uk
Hypertension is the main global risk factor for cardiovascular disease. Despite this, less than
half of treated hypertensive patients are controlled. One reason for this is nonadherence, a …
half of treated hypertensive patients are controlled. One reason for this is nonadherence, a …
Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension.
ML Addison, P Ranasinghe, DJ Webb - Expert Review of Clinical …, 2023 - europepmc.org
Hypertension is the main global risk factor for cardiovascular disease. Despite this, less than
half of treated hypertensive patients are controlled. One reason for this is nonadherence, a …
half of treated hypertensive patients are controlled. One reason for this is nonadherence, a …
Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension
ML Addison, P Ranasinghe… - Expert review of clinical … - pubmed.ncbi.nlm.nih.gov
Introduction Hypertension is the main global risk factor for cardiovascular disease. Despite
this, less than half of treated hypertensive patients are controlled. One reason for this is …
this, less than half of treated hypertensive patients are controlled. One reason for this is …